Guardant Health. has been granted a patent for methods to identify genetic variants, specifically copy number variations, in DNA samples. The patented method involves tagging, amplifying, and sequencing DNA, ultimately detecting BRAF V600E mutations to guide treatment with dabrafenib for non-small cell lung cancer. GlobalData’s report on Guardant Health gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Guardant Health, Personalized medicine biomarkers was a key innovation area identified from patents. Guardant Health's grant share as of July 2024 was 26%. Grant share is based on the ratio of number of grants to total number of patents.
Methods for detecting genetic variants in cancer treatment
The granted patent US12054774B2 outlines a method for treating non-small cell lung cancer (NSCLC) by detecting a specific genetic variant associated with the BRAF V600E mutation. The method involves several steps, starting with the collection of a sample containing double-stranded DNA (dsDNA) from the subject. This sample undergoes a series of processes, including the attachment of molecular barcodes to the DNA, amplification of the tagged DNA, and sequencing to generate a set of sequencing reads. These reads are then mapped to a reference sequence, and redundancy is reduced or tracked using the sequence information from the molecular barcodes. The final steps include generating consensus sequences from the mapped reads and detecting the presence of the BRAF V600E mutation, which is critical for determining the appropriate treatment.
In addition to the primary method, the patent specifies that the DNA sample may consist of cell-free DNA (cfDNA) and outlines various parameters for the amplification and tagging processes. The method allows for selective enrichment of genomic regions of interest, particularly those related to the BRAF gene. Furthermore, it includes quantitative measures to assess the presence of paired and unpaired reads, which contribute to a comprehensive understanding of the genetic landscape of the tumor. Ultimately, upon confirming the presence of the BRAF V600E mutation, the method prescribes the administration of dabrafenib, a targeted therapy, to effectively treat the NSCLC in the subject.
To know more about GlobalData’s detailed insights on Guardant Health, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
